[1] L. Jia, N. Han, J. Du, L. Guo, Z. Luo, and Y. Liu, “Pathogenesis of important virulence factors of Porphyromonas gingivalis via toll-like receptors,” Front. Cell. Infect. Microbiol., vol. 9, p. 262, 2019.
[2] F. D’Aiuto et al., “Evidence summary: The relationship between oral diseases and diabetes,” Br. Dent. J., vol. 222, no. 12, pp. 944–948, 2017.
[3] C. Huang and G. Shi, “Smoking and microbiome in oral, airway, gut and some systemic diseases,” J. Transl. Med., vol. 17, no. 1, pp. 1–15, 2019.
[4] F. R. M. Leite, G. G. Nascimento, F. Scheutz, and R. Lopez, “Effect of smoking on periodontitis: a systematic review and meta-regression,” Am. J. Prev. Med., vol. 54, no. 6, pp. 831–841, 2018.
[5] I. Al-Assaf and M. Khazem, “Antioxidant Activity of Total phenols and Flavonoids extracted from Echinops polyceras roots grown in Syria,” Iraqi J. Pharm. Sci. (P-ISSN 1683-3597 E-ISSN 2521-3512), vol. 30, no. 2, pp. 261–268, 2021.
[6] S. Anil, “Study of the patterns of periodontal destruction in smokers with chronic periodontitis,” Indian J. Dent. Res., vol. 19, no. 2, p. 124, 2008.
[7] M. A. El-Missiry, Z. M. A. El-Missiry, and A. I. Othman, “Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19,” Eur. J. Pharmacol., vol. 882, p. 173329, 2020.
[8] D. Acuña-Castroviejo et al., “Extrapineal melatonin: sources, regulation, and potential functions,” Cell. Mol. life Sci., vol. 71, pp. 2997–3025, 2014.
[9] S. D. Paredes, A. Korkmaz, L. C. Manchester, D.-X. Tan, and R. J. Reiter, “Phytomelatonin: a review,” J. Exp. Bot., vol. 60, no. 1, pp. 57–69, 2009.
[10] H. R. Hasan and J. A. Zainulabdeen, “Screening, Extraction, and Quantification of Melatonin in Waste of Some Plants,” Iraqi J. Sci., pp. 1874–1884, 2022.
[11] A. Cutando, G. Gómez‐Moreno, C. Arana, D. Acuña‐Castroviejo, and R. J. Reiter, “Melatonin: potential functions in the oral cavity,” J. Periodontol., vol. 78, no. 6, pp. 1094–1102, 2007.
[12] M. Gunata, H. Parlakpinar, and H. A. Acet, “Melatonin: A review of its potential functions and effects on neurological diseases,” Rev. Neurol. (Paris)., vol. 176, no. 3, pp. 148–165, 2020.
[13] N. Suzuki, M. Somei, A. Seki, R. J. Reiter, and A. Hattori, “Novel bromomelatonin derivatives as potentially effective drugs to treat bone diseases,” J. Pineal Res., vol. 45, no. 3, pp. 229–234, 2008.
[14] T. M. Balaji and S. R. Rao, “Salivary, Plasma, and Gingival Levels of Melatonin and TNF-α in Nonsmokers and Current Smokers with and without Periodontal Disease,” J. Contemp. Dent. Pract., vol. 21, no. 8, pp. 897–904, 2020.
[15] K. Bjartveit and A. Tverdal, “Health consequences of smoking 1–4 cigarettes per day,” Tob. Control, vol. 14, no. 5, pp. 315–320, 2005.
[16] M. S. Tonetti, H. Greenwell, and K. S. Kornman, “Staging and grading of periodontitis: Framework and proposal of a new classification and case definition,” J. Periodontol., vol. 89, pp. S159–S172, 2018.
[17] M. Navazesh, “Methods for collecting saliva,” Ann. N. Y. Acad. Sci., vol. 694, no. 1, pp. 72–77, 1993.
[18] T. Meulman et al., “Impact of supragingival therapy on subgingival microbial profile in smokers versus non-smokers with severe chronic periodontitis,” J. Oral Microbiol., vol. 4, no. 1, p. 8640, 2012.
[19] L. R. A. Ameer and B. G. Ali, “Effects of light smoking on salivary levels of alkaline phosphatase and osteocalcin in chronic periodontitis patients,” J. Baghdad Coll. Dent., vol. 27, no. 2, pp. 110–114, 2015.
[20] M. BinShabaib et al., “Clinical periodontal status and gingival crevicular fluid cytokine profile among cigarette-smokers, electronic-cigarette users and never-smokers,” Arch. Oral Biol., vol. 102, pp. 212–217, 2019.
[21] K. Edman, K. Öhrn, B. Nordström, A. Holmlund, and D. Hellberg, “Trends over 30 years in the prevalence and severity of alveolar bone loss and the influence of smoking and socio‐economic factors–based on epidemiological surveys in Sweden 1983–2013,” Int. J. Dent. Hyg., vol. 13, no. 4, pp. 283–291, 2015.
[22] J. Katz, R. M. Caudle, I. Bhattacharyya, C. M. Stewart, and D. M. Cohen, “Receptor for advanced glycation end product (RAGE) upregulation in human gingival fibroblasts incubated with nornicotine,” J. Periodontol., vol. 76, no. 7, pp. 1171–1174, 2005.
[23] H. Abdolsamadi et al., “Reduction of melatonin level in patients with type II diabetes and periodontal diseases,” J. Dent. Res. Dent. Clin. Dent. Prospects, vol. 8, no. 3, p. 160, 2014.
[24] R. S. Hassan and S. A. Salman, “Evaluation of Salivary Melatonin and Periodontal Parameters in Type II Diabetic Patients with Chronic Periodontitis: A Comparative Study.,” Indian J. Public Heal. Res. Dev., vol. 10, no. 10, 2019.
[25] K. Lodhi, C. S. Saimbi, M. A. Khan, C. Nath, and R. Shukla, “Evaluation of melatonin levels in saliva in gingivitis and periodontitis cases: A pilot study,” Contemp. Clin. Dent., vol. 7, no. 4, p. 519, 2016.
[26] R. J. Reiter, J. C. Mayo, D. Tan, R. M. Sainz, M. Alatorre‐Jimenez, and L. Qin, “Melatonin as an antioxidant: under promises but over delivers,” J. Pineal Res., vol. 61, no. 3, pp. 253–278, 2016.
[27] N. Buduneli et al., “Effects of smoking and gingival inflammation on salivary antioxidant capacity,” J. Clin. Periodontol., vol. 33, no. 3, pp. 159–164, 2006.
[28] Z. Donmez et al., “Evaluation of the antioxidant effects of melatonin on the larynx mucosa of rats exposed to environmental tobacco smoke,” Clin. Otolaryngol., vol. 41, no. 3, pp. 211–221, 2016.
[29] R. Srinath, A. B. Acharya, and S. L. Thakur, “Salivary and gingival crevicular fluid melatonin in periodontal health and disease,” J. Periodontol., vol. 81, no. 2, pp. 277–283, 2010.
[30] S. Najeeb, Z. Khurshid, S. Zohaib, and M. S. Zafar, “Therapeutic potential of melatonin in oral medicine and periodontology,” Kaohsiung J. Med. Sci., vol. 32, no. 8, pp. 391–396, 2016.